Stab Therapeutics

What Stab Therapeutics does

Stab Therapeutics is a clinical-stage biotechnology spin-off of the Instituto de Investigacion Hospital 12 de Octubre (imas12) in Madrid, Spain, founded in 2023 with support from the CRIS Foundation. The company develops next-generation immune-redirecting cell therapies for solid and hematological tumors, applying a proprietary STAb immunotherapy platform that combines the principles of adoptive cell therapy and bispecific antibodies. The core mechanism is the in vivo production of T cell-engagers (TCE) by engineered cells, which yields sustained serum TCE concentrations, expansion and persistence of adoptively transferred STAb-T cells, and polyclonal recruitment of both modified and unmodified bystander T cells at the tumor microenvironment, leading to enhanced antitumor responses preclinically validated in B-cell and T-cell hematological malignancies.

The lead clinical asset is STAb-T19, a cellular immunotherapy targeting relapsed or refractory CD19-positive B-cell malignancies (including B-cell acute lymphoblastic leukemia and B-cell lymphomas, which together represent roughly 85% of pediatric ALL, 75% of adult ALL, and 85% of all lymphomas). STAb-T19 entered Phase I clinical trials in early 2024, with IND-enabling validation funded by Comunidad de Madrid and FEDER and the First-in-Human trial supported by Instituto de Salud Carlos III. The company is led by CEO Dr. Carolina Pola (appointed December 2023, formerly of Nature Medicine, PharmaMar, CNIO) and Co-Founder/CSO Dr. Belen Blanco, with a Scientific Advisory Board including Luis Alvarez-Vallina, Luis Paz-Ares, Joaquin Martinez, and Richard G. Vile.

The business is pre-revenue and operates on non-dilutive grant funding, including an 80,000 euro 2023 grant from the Consejeria de Educacion, Ciencia y Universidades (Comunidad de Madrid) and recognition in the Madri+d Healthstart program. With 1-10 employees, no commercial product, and no disclosed pharma licensing deal, the future revenue model is expected to flow from clinical development milestones, partnership or out-licensing transactions with larger pharmaceutical companies, and ultimately commercialization of cell therapies for oncology indications where current cure rates do not exceed 50-60%.

Name

Stab Therapeutics

Legal name

Stab Therapeutics

Website

https://stabtherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Stab Therapeutics is a Madrid-based, pre-revenue biotech spin-off of Hospital 12 de Octubre developing STAb-T cell therapies for B-cell malignancies and solid tumors via a proprietary platform combining adoptive cell therapy with bispecific antibody principles.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cell therapy platform
• T cell engagers
• Adoptive cell therapy
• Cancer immunotherapy
• Hematological malignancy treatment

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Others

Marketing channels3 records

Core offering

Stab Therapeutics develops immune-redirecting T cell therapies for solid and hematological tumors using an adoptive cell therapy approach. Its STAb immunotherapy platform combines adoptive cell therapy with bispecific antibody principles through in vivo production of T cell-engagers by engineered cells, and the lead clinical candidate STAb-T19 targets relapsed or refractory CD19-positive B-cell malignancies, including B-cell leukemias and lymphomas.

Product overview

STAb Therapeutics is developing a novel cell therapy platform based on STAb immunotherapy - a T cell redirecting strategy that combines adoptive cell therapy and bispecific antibody principles. The core technology relies on in vivo production of T cell-engagers (TCE) by engineered cells. The primary product is STAb-T19, a cellular immunotherapy targeting CD19-positive B-cell malignancies (leukemias and lymphomas), which is entering clinical trials. The platform is designed to be versatile and applicable to both hematological and solid tumors.

Differentiator

Problem solved

Functional benefit

Products and services

• STAb-T19 STAb-T19 is a cellular cancer immunotherapy that uses a T cell redirecting approach based on in vivo production of T cell-engagers (TCE) by engineered STAb-T cells. It is designed as a treatment for patients with relapsed or refractory CD19-positive B-cell malignancies, including B-cell leukemias and lymphomas, where conventional therapies result in cure rates that do not exceed 50-60% of patients.
• STAb Immunotherapy Platform STAb immunotherapy is a T cell redirecting strategy combining adoptive cell therapy and bispecific antibody principles, based on in vivo production of T cell-engagers (TCE) by engineered cells. The platform enables effective serum concentrations of TCE, expansion and persistence of adoptively transferred STAb-T cells, and polyclonal recruitment of both modified and unmodified bystander T cells at the tumor microenvironment. It is designed as a versatile platform applicable to both hematological and solid tumors.

Quantifiable outcome

• STAb-T19 entered clinical trials in early 2024 for relapsed or refractory CD19-positive B-cell malignancies
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Instituto de Investigacion Hospital 12 de Octubre i+12coreStrategic or Co-development PartnerSTAb Therapeutics is a spin-off company from the Instituto de Investigacion Hospital 12 de Octubre (imas12). The Immuno-Oncology and Immunotherapy group, led by Dr. Luis Alvarez-Vallina, developed the STAb-T19 immunotherapy and continues to be the scientific foundation of the company.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/STAbtherapeutic
• LinkedInlinkedin.com/company/stab-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stab Therapeutics